Alex Pasteur

Venture Capitalist and Partner at F-Prime Capital Partners

Alex Pasteur is a Partner at F-Prime Capital based in London.2 He has been working in healthcare investing since 2001 and focuses on investments in therapeutics and healthcare IT.1 2

Some key points about Alex Pasteur:

Professional Experience

Partner at F-Prime Capital since October 20123
Board Observer at Castor since July 20213
Previously worked at MVM Life Science Partners LLP in the US and Europe from 2005 to 20121 2

Education

Ph.D. in Chemistry from the University of Cambridge1 2 3
M.A. in Natural Sciences from the University of Cambridge1 2 3

Investment Portfolio

Alex Pasteur's investment portfolio includes or has included companies such as:

Castor (Ciwit B.V.)1 2
Acacia Pharma Group (acquired by Eagle Pharmaceuticals)2
Adaptimmune Therapeutics (NASDAQ: ADAP)1 2
Arvelle Therapeutics (acquired by Angelini Pharma)1 2
Genomics PLC1 2
Orchard Therapeutics (NASDAQ: ORTX)1 2
Oviva AG1 2
Owkin Inc.1 2
Pulmocide Ltd.2 3

Additional Roles

Alex Pasteur also serves as a board member or director for several companies, including:

Tenpoint Therapeutics3
NodThera Limited3
Oviva3
Owkin3

His experience and expertise in healthcare investing, combined with his scientific background, make him a valuable asset in the biotech and healthcare investment sectors.

Highlights

Jan 22 · biomarker.substack.com

F-Prime: Alex Pasteur, PhD - Biomarker - Substack

Experience

Partner at F-Prime Capital Partners (October 2012 - Present)

Director at Tenpoint Therapeutics (December 2020 - Present), Director at NodThera Limited (February 2018 - Present), Director at Oviva (September 2016 - Present), Director at Owkin (March 2019 - Present), Director at Arvelle Therapeutics (February 2020 - January 2021), Director at Acacia Pharma (August 2013 - March 2018), Board Observer at Genomics plc (January 2018 - Present), Board Observer at Castor (July 2021 - Present), Board Observer at Pulmocide (December 2013 - Present), Board Observer at Adaptimmune Therapeutics PLC (September 2015 - May 2016), Partner at MVM (2005 - 2012), Investment Manager at Gateway Fund (2001 - 2005)

Education

PhD in Chemistry from University of Cambridge (1992 - 1996), Master of Arts (MA) in Natural Sciences from University of Cambridge (1989 - 1992) - Specialized in Chemistry, Cell Biology